. . . . . . . "T-1249 is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast track designation from the FDA and is in Phase I/II clinical testing."@en . . . . . "T-1249 binds to a slightly different region of the HIV virus than Fuzeon (enfuvirtide). As a result,it exhibits activity against Fuzeon-resistant viruses. T-1249 is designed to block fusion of HIV with host cells before the virus enters the cell and begins its replication process."@en . "T-1249"@en . . . . . . . . . . . . . "investigational"@en . . "Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection."@en . .